Abstract
Although HPV16 has been strongly implicated in oropharyngeal carcinogenesis, the role of other high-risk HPV types in the etiology of head and neck cancer remains unclear. To date, few data exist addressing the nature of the association between antibodies to oncogenic proteins of non-HPV16 HPVs in relation to head and neck cancer. We examined the relationship between multiple HPV types (HPV6, 11, 16, 18, 31, 33, 45, 52, 58) and head and neck squamous cell carcinoma (HNSCC) in a large population-based case-control study (1069 cases and 1107 controls). Serological measures for HPV types included antibodies to L1, E6 and/or E7. In a secondary analysis, we excluded HPV16 seropositive subjects to examine independent associations with other high-risk HPVs. All analyses were adjusted for age, race, sex, education, smoking, and alcohol consumption. Statistically significant associations were observed for HPV16, 18, 33, and 52 and risk of HNSCC after mutually adjusting for HPV types. Among HPV16 seronegative subjects, elevated risks of HNSCC were observed for HPV18 E6 (OR = 4.19, 95% CI = 1.26–14.0), HPV33 E6 (OR = 7.96, 95% CI = 1.56–40.5), and HPV52 E7 (OR = 3.40, 95% CI = 1.16–9.99). When examined by tumor type, associations with HPV18 and HPV33 remained statistically significant for oropharyngeal cancer, and HPV52 was associated with oral cancer. In addition, magnitude of associations for HNSCC increased dramatically with increasing number of seropositive high-risk HPV infections. High-risk HPV types, other than HPV16, are likely to be involved in the etiology of HNSCC.
Keywords: HPV infection, head and neck cancer, oropharyngeal cancer, oral cancer
Introduction
Incidence rates for oral cavity and laryngeal cancers have been decreasing rapidly over the past two decades, while oropharyngeal cancer rates have been increasing by an average of 2.9% annually between 2001–2010 1. The substantial decrease in oral cavity and laryngeal cancer rates, observed in the US and other countries 2, 3, is likely due to changes in cigarette smoking patterns, whereas the increase in oropharyngeal cancer rates may reflect changes in behaviors that increase exposure to human papillomavirus (HPV) 4. The majority (>90%) of oral, pharyngeal and laryngeal cancers (collectively referred to as head and neck cancers) derive from a squamous epithelial origin 5.
The association between HPV16 and risk of head and neck squamous cell carcinoma (HNSCC), while relatively newly discovered, is well-documented 6–8. In addition, HPV16-positive HNSCCs display different risk factors than HPV16-negative cancers, and are likely to be distinct from those caused by tobacco and alcohol 9, 10. Although HPV subtypes other than HPV16 are suspected to play a role in HNSCC, given their oncogenic potential and associations with anogenital cancers 11, only a few epidemiologic studies have examined HPV types in HNSCC while controlling for HPV16 infection or after excluding HPV16 seropositive subjects 12, 13.
We previously published results for HPV types and risk of HNSCC using the first phase of our case-control study 6; we reported positive associations for HPV6 and 18, adjusting for HPV16. In the current analysis, we include subjects from the second phase of the study (effectively doubling the sample size) and add measures for five additional HPV types (HPV31, 33, 45, 52, and 58). Furthermore, with our large sample size (1069 cases and 1107 controls), we were able to examine high-risk, non-HPV16 HPVs among HPV16 seronegative subjects.
Methods
Study population
Incident cases of HNSCC were identified in the geographic greater Boston area and recruited from head and neck clinics and departments of otolaryngology or radiation oncology at the major teaching hospitals in the region (Brigham and Women’s Hospital, Beth Israel Deaconess Medical Center, Boston Medical Center, Dana-Farber Cancer Institute, Massachusetts Eye and Ear Infirmary, Massachusetts General Hospital, and New England Medical Center). Patients with a confirmed incident diagnosis of HNSCC were included if they were residents in the study area and 18 years or older. Recurrent cases and incident cases diagnosed more than 6 months prior to contact were excluded. HNSCC cases consist of those with a diagnosis code of 141, 143–146, 148, 149, or 161 based on the International Classification of Disease, Ninth Revision (ICD-9). Greater than 90% of the incident cases reported to the state cancer registry for the study period in the catchment area were identified and approached for participation. Controls were selected from the same population and frequency-matched to cases by sex, age (+/− 3 yrs), and town of residence using the Massachusetts town lists. The study population for this analysis includes data collected from two periods of recruitment from the same population: the first period was between December 1999 and December 2003 (Phase I) and the second was between October 2006 and June 2011 (Phase II). Participation rates for cases and controls were 78% and 47%, respectively. A total of 1069 cases and 1107 controls provided blood upon enrollment during the two phases. All cases and controls enrolled in the study provided written informed consent as approved by the Institutional Review Boards of the participating institutions.
To examine disease by site, tumors were classified as oral cavity (ICD-9 codes 141.1–141.5, 141.8, 141.9, 143–145.2, 145.5–145.9, 149.8, 149.9), pharynx (ICD-9 codes 141.0, 141.6, 145.3, 145.4, 146, 148, 149.0, 149.1), or larynx (ICD-9 code 161) in accordance with the recommendations of the American Joint Committee on Cancer. Nasopharyngeal cancers were not included in this study.
HPV serology measurement
Serum from venous blood was separated within 12–24 hr of blood drawing and stored at −80°C. To detect antibodies against HPV L1, E1, E2, E4, E6 and E7 proteins, a glutathione S-transferase capture enzyme-linked immunosorbent assay (ELISA) was used in combination with fluorescent bead 14, 15. This assay detects HPV antibodies with high type specificity and demonstrates assay sensitivity similar to the “gold-standard” for L1-serology that uses virus-like particles (VLP) as antigens 15. L1 antibodies were measured for HPV types 6, 11, 16, 18, 31, 33, and 45. E6 antibodies were measured for all except HPV6, and E7 on all except HPV6, 31, 33, and 45. Finally antibodies for E1, E2, and E4 were measured on HPV16 and 18.
Additional exposure assessment
Cases and controls responded to a self-administered questionnaire to collect data on demographic characteristics, medical history (including asthma and allergies), family history of cancer, detailed smoking (including marijuana use) and alcohol consumption habits, occupational history, and residential history. Questionnaires were provided to cases during their initial clinic visit and were mailed to controls, and were returned and reviewed by study personnel during the second visit for cases and first in-person visit for controls.
Statistical Analysis
Case and control differences across baseline characteristics were assessed using ANOVA and controlling for sex and age. Odds ratios (OR) and 95% confidence intervals (CIs) were estimated for HPV status using unconditional logistic regression and controlling for known risk factors, including age, sex, race (white or other), smoking status (ever/never), smoking (pack-years as a continuous variable), average alcohol drinks per week (continuous), education (less/high school graduate or more), and study phase (I/II). We applied multiple imputation methods using age and sex to assign values to missing values for race (0.2% missing), education (7% missing), alcohol (7% missing), marijuana (7%) and pack-years (6.7% missing); using multiple imputation for missing data reduces bias 16, 17. Additional control for body mass index (BMI), income (below/above $50K per year), or marijuana use, did not change the observed associations and were left out of the final model. To examine if different subtypes of HPV were associated with HNSCC independently of HPV16 infection, we conducted additional analyses among those who were HPV16 seronegative for E6, E7 or L1 (611 cases; 967 controls). In addition, we conducted analyses to examine whether there are any multiplicative interactions with HPV16 seropositive status and high-risk HPV types, as well as with allergy history; tests for interaction were conducted using cross-product terms in the logistic regression models. Finally, to examine the role of co-infections, we examined associations for multiple infections.
All analyses were conducted in R (Version 2.14) and all tests were two-sided. Multiple imputations were carried out using the R package mi 18.
Results
The distributions of known risk factors of HNSCC by case-control status for this study have been previously published 19. Briefly, smoking, alcohol consumption, and HPV16 seropositivity were higher among cases than controls, and controls were more educated than cases. The mean age was 60.7 years among cases and 59.4 among controls, 74% of subjects were males, and most subjects were white (92% cases and 91% controls). The prevalence of HPV16 seropositivity for E6/E7 antibodies among controls was 6.8%, and 8% for other high-risk HPV types (Table 1); about 1% of controls were positive for both HPV16 and other high-risk HPV types. Controls were more likely to be seropositive for HPV16 or other HPV types if they were older, women, non-Caucasian, high-school graduates (vs. some college), and smokers (for HPV16 only). While HPV16 seropositive controls were more likely to be high alcohol consumers, the opposite trend was observed for other high-risk HPV types.
Table 1.
Descriptive demographic and lifestyle statistics among controls, stratified by HPV16 status, and separately by non-HPV16, high risk HPV status.
| Characteristic | HPV 16* seronegative (N = 1031) | HPV 16 seropositive (N = 75) | High Risk** seronegative (N = 1018) | High Risk seropositive (N = 89) |
|---|---|---|---|---|
| Age | ||||
| Mean (sd) | 60.5 (11.0) | 62.6 (12.2) | 60.7 (11.2) | 60.9 (10.5) |
| Sex | ||||
| Male | 760 (73.7) | 59 (78.7) | 749 (73.6) | 71 (79.8) |
| Female | 271 (26.3) | 16 (21.3) | 269 (26.4) | 18 (20.2) |
| Race | ||||
| White | 944 (91.6) | 62 (82.7) | 927 (91.1) | 80 (89.9) |
| Other | 87 (8.4) | 13 (17.3) | 91 (8.9) | 9 (10.1) |
| Education | ||||
| High school graduate | 280 (27.2) | 25 (33.3) | 276 (27.1) | 29 (32.6) |
| At least some college | 747 (72.5) | 50 (66.7) | 738 (72.5) | 60 (67.4) |
| Smoking, pack years | ||||
| None | 420 (40.7) | 22 (29.3) | 408 (40.1) | 34 (38.2) |
| First tertile (>0 to 18) | 215 (20.9) | 14 (18.7) | 214 (21.0) | 15 (16.9) |
| Second tertile (18 to 41) | 199 (19.3) | 20 (26.7) | 198 (19.4) | 21 (23.6) |
| Third tertile (>41) | 197 (19.1) | 19 (25.3) | 198 (19.4) | 19 (21.3) |
| Average alcohol drinks/wk | ||||
| First quartile (≤2) | 252 (24.4) | 16 (21.3) | 245 (24.1) | 24 (27.0) |
| Second quartile (2–6) | 298 (28.9) | 20 (26.7) | 292 (28.7) | 26 (29.2) |
| Third quartile (6–14) | 236 (22.9) | 11 (14.7) | 227 (22.3) | 20 (22.5) |
| Fourth quartile (>14) | 242 (23.5) | 28 (37.3) | 252 (24.8) | 18 (20.2) |
| Age of first intercourse | ||||
| Mean (sd) | 18.8 (3.6) | 18.7 (3.8) | 18.8 (3.8) | 18.7 (2.9) |
| Allergy | ||||
| No | 596 (57.8) | 45 (60.0) | 593 (58.3) | 48 (53.9) |
| Yes | 389 (37.7) | 29 (38.7) | 381 (37.4) | 38 (42.7) |
HPV16 positive for E6, and/or E7.
Positive for HPV18 (E6/E7), 31 (E6), 33 (E6), 45 (E6), 52 (E6/E7), and/or 58 (E6/E7).
Table 2 provides population characteristics by case/control status. As expected, smoking and alcohol, and HPV16 were strongly associated with case status. In addition, cases were less educated than controls, and had a slightly earlier age at first intercourse (p-value 0.02). Table 3 provides correlation coefficients between different HPV types; HPV33 and HPV58 were mostly strongly correlated with HPV16 (r=0.41 and r=0.27, respectively).
Table 2.
Descriptive demographic and lifestyle statistics by HNSCC case-control status.
| Characteristic | Cases (N = 1069) | Controls (N = 1107) | P-value* |
|---|---|---|---|
| Age | |||
| Mean (sd) | 59.4 (11.4) | 60.7 (11.1) | |
| Sex | |||
| Male | 798 (74.6) | 820 (74.1) | |
| Female | 271 (25.4) | 287 (25.9) | |
| Race | |||
| White | 985 (92.1) | 1007 (91.0) | 0.23 |
| Other | 82 (7.7) | 100 (9.0) | |
| Education | |||
| High school graduate | 376 (35.2) | 305 (27.6) | <0.001 |
| At least some college | 547 (51.2) | 276 (72.1) | |
| Smoking, pack years | |||
| None | 230 (21.5) | 442 (39.9) | <0.001 |
| First tertile (>0 to 18) | 205 (19.2) | 255 (23.0) | |
| Second tertile (18 to 41) | 222 (20.8) | 227 (20.5) | |
| Third tertile (>41) | 268 (25.1) | 283 (16.5) | |
| Average alcohol drinks/wk | |||
| First quartile (≤3) | 210 (19.6) | 348 (31.4) | <0.001 |
| Second quartile (3–7) | 167 (15.6) | 293 (26.5) | |
| Third quartile (7–21) | 226 (21.1) | 291 (26.3) | |
| Fourth quartile (>21) | 318 (29.7) | 172 (15.5) | |
| Age at first intercourse | |||
| Mean (sd) | 18.2 (3.5) | 18.8 (3.6) | 0.02 |
| Allergy | |||
| No | 602 (56.3) | 641 (57.9) | 0.001 |
| Yes | 292 (27.3) | 419 (37.9) | |
| HPV 16** | |||
| Negative | 674 (63.0) | 1031 (93.1) | <0.001 |
| Positive | 395 (37.0) | 75 (6.8) |
Adjusted for age and gender.
HPV16 positive for E6, and/or E7.
Table 3.
Correlation coefficients for measures of HPV (any positive E6 and/or E7 vs. all negative) among cases and controls (N = 2176).
| HPV type | 6 | 11 | 16 | 18 | 31 | 33 | 45 | 52 | 58 |
|---|---|---|---|---|---|---|---|---|---|
| 6 | 1 | ||||||||
| 11 | 0.07 | 1 | |||||||
| 16 | 0.12 | 0.10 | 1 | ||||||
| 18 | 0.04 | 0.11 | 0.12 | 1 | |||||
| 31 | 0.00 | 0.03 | 0.05 | 0.14 | 1 | ||||
| 33 | 0.08 | 0.09 | 0.41 | 0.10 | 0.12 | 1 | |||
| 45 | 0.02 | 0.14 | 0.08 | 0.13 | 0.16 | 0.17 | 1 | ||
| 52 | 0.01 | 0.06 | 0.06 | 0.00 | −0.01 | 0.13 | 0.04 | 1 | |
| 58 | 0.07 | 0.02 | 0.27 | 0.01 | 0.05 | 0.47 | 0.07 | 0.33 | 1 |
In the main analyses, we observed positive associations for HNSCC with all HPV subtypes after adjusting for HPV16 seropositivity for non-HPV16 subtypes (although HPV31 and HPV45 were not statistically significant; Table 4). After mutually controlling for all HPV types, statistically significant associations remained for all HPV16 viral protein antibodies, HPV18 E6, HPV33 E6, and HPV52 E7 (Table 4). With the exception of HPV31, all HPV types were strongly associated with pharyngeal cancer (Table 5; HPV16 E6 seropositive: OR = 81.2, 95% CI = 51.1–128.9). For oral cavity cancers, statistically significant 2-fold or greater increases in risk were observed for HPV16 (HPV16 seropositive, E6: OR = 6.76, 95% CI = 3.95–11.6; E7: OR = 2.93, 95% CI = 1.87–4.59), HPV18 E6, HPV33 E6, HPV52 E7 and HPV58 E6 (Table 5). For laryngeal cancers, statistically elevated risks were observed for HPV16 (E6: OR = 5.64, 95% CI = 2.89–11.0; E7: OR = 2.95, 95% CI = 1.65–5.26), and HPV33 (E6: OR = 14.2, 95% CI = 4.43–45.8); Table 5). Including L1-positive serology in the analysis (vs. only E6/E7 positivity) increased the overall number of subjects who were HPV seropositive (e.g., 12.5% of controls positive for HPV16 E6, E7 or L1 vs. 6.8% of controls positive for HPV16 E6 or E7), but attenuated the associations between the different HPVs and risk of HNSCC (e.g., HPV16 OR = 1.40, 95% CI = 1.33–1.47).
Table 4.
Odds ratios and 95% CI for HPV 6, 11, 16, 18, 31, 33, 45, 52, and 58 positive serology in relation to head and neck cancer.
| HPV type | Case/Control Seropositive No. | OR (95% CI)* | OR (95% CI)** | p-value** |
|---|---|---|---|---|
| HPV 6 L1 | 140/118 | 0.83 (0.62, 1.13) | 0.88 (0.63, 1.23) | 0.45 |
|
| ||||
| HPV 11 L1 | 149/93 | 0.75 (0.53, 1.05) | 0.82 (0.55, 1.21) | 0.31 |
| HPV 11 E6 | 11/10 | 0.82 (0.27, 2.48) | 0.59 (0.18, 1.89) | 0.43 |
| HPV 11 E7 | 14/2 | 6.75 (1.46, 30.9) | NA | NA |
|
| ||||
| HPV 16 L1 | 298/73 | 6.80 (5.10, 9.06) | 7.06 (4.03, 9.89) | <0.0001 |
| HPV 16 E6 | 346/25 | 30.6 (19.9, 47.2) | 21.7 (13.9, 34.0) | <0.0001 |
| HPV 16 E7 | 137/51 | 3.69 (2.59, 5.25) | 5.35 (3.39, 8.46) | <0.0001 |
|
| ||||
| HPV 18 L1 | 245/177 | 0.93 (0.72, 1.21) | 1.00 (0.74, 1.35) | 0.99 |
| HPV 18 E6 | 31/4 | 8.73 (2.88, 26.4) | 7.38 (2.32, 23.5) | 0.001 |
| HPV 18 E7 | 54/20 | 2.72 (1.57, 4.70) | 1.70 (0.31, 9.40) | 0.54 |
|
| ||||
| HPV 31 L1 | 174/95 | 1.20 (0.87, 1.64) | 1.11 (0.51, 2.39) | 0.80 |
| HPV 31 E6 | 50/38 | 1.20 (0.71, 2.02) | 0.79 (0.44, 1.41) | 0.42 |
|
| ||||
| HPV 33 L1 | 160/81 | 1.07 (0.75, 1.52) | 1.31 (0.93, 1.85) | 0.12 |
| HPV 33 E6 | 121/5 | 7.40 (2.77, 19.8) | 4.82 (1.57, 14.8) | 0.006 |
|
| ||||
| HPV 45 L1 | 145/90 | 0.74 (0.52, 1.06) | 0.73 (0.48, 1.11) | 0.14 |
| HPV 45 E6 | 20/8 | 1.82 (0.68, 4.88) | 0.64 (0.19, 2.22) | 0.48 |
|
| ||||
| HPV 52 E6 | 16/0 | NA | NA | NA |
| HPV 52 E7 | 19/6 | 3.56 (1.32, 9.60) | 3.31 (1.08, 10.1) | 0.04 |
|
| ||||
| HPV 58 E6 | 87/4 | 4.89 (1.60, 15.0) | 1.97 (0.58, 6.70) | 0.28 |
| HPV 58 E7 | 31/17 | 1.62 (0.82, 3.21) | 1.11 (0.51, 2.39) | 0.80 |
Adjusted for age, race, gender, education, tobacco smoking, alcohol use, study phase, and HPV16 (for all non-HPV16 types). HPV 52 and 58 E7 not adjusted for phase because they were only measured for phase 1.
Additionally mutually adjusting for HPV types in table; p-values presented are for these associations
Table 5.
Odds ratios and 95% CI for HPV 6, 11, 18, 31, 33, 45, 52, and 58 positive serology (E6, E7) in relation to different sites of head and neck cancer.
| HPV type | Controls, Sero- positive No. |
Oral cavity (N=400) Seropositive No. |
Oral cavity OR* (95% CI) |
Oral cavity p-value |
Pharyngeal (N=486) Seropositive No. |
Pharyngeal OR* (95% CI) |
Pharyngeal p-value |
Laryngeal (N=168) Seropositive No. |
Laryngeal OR* (95% CI) |
Laryngeal p-value |
|---|---|---|---|---|---|---|---|---|---|---|
| HPV 16 E6 | 25 | 42 | 6.76 (3.95, 11.6) | <0.001 | 281 | 81.2 (51.1, 128.9) | <0.001 | 19 | 5.64 (2.89, 11.0) | <0.001 |
| HPV 16 E7 | 51 | 44 | 2.93 (1.87, 4.59) | <0.001 | 68 | 3.33 (2.25, 4.93) | <0.001 | 22 | 2.95 (1.65, 5.26) | <0.001 |
|
| ||||||||||
| HPV 18 E6 | 4 | 10 | 5.47 (1.58, 18.9) | 0.01 | 18 | 10.7 (3.53, 32.4) | <0.001 | 2 | 3.23 (0.56, 18.6) | 0.19 |
| HPV 18 E7 | 9 | 20 | 1.23 (0.54, 2.81) | 0.62 | 40 | 5.01 (2.87, 8.77) | <0.001 | 4 | 0.92 (0.28, 3.04) | 0.90 |
|
| ||||||||||
| HPV 31 E6 | 38 | 19 | 1.53 (0.85, 2.75) | 0.16 | 24 | 1.61 (0.94, 2.75) | 0.08 | 7 | 1.13 (0.47, 2.72) | 0.79 |
|
| ||||||||||
| HPV 33 E6 | 5 | 19 | 14.2 (5.12, 39.2) | <0.001 | 92 | 52.8 (21.2, 131.5) | <0.001 | 10 | 14.2 (4.43, 45.8) | <0.001 |
|
| ||||||||||
| HPV 45 E6 | 8 | 2 | 0.63 (0.13, 3.16) | 0.57 | 17 | 5.05 (2.14, 11.9) | <0.001 | 1 | 0.56 (0.06, 5.25) | 0.61 |
|
| ||||||||||
| HPV 52 E7 | 6 | 8 | 3.80 (1.21, 11.9) | 0.02 | 8 | 4.03 (1.30, 12.5) | 0.02 | 3 | 2.13 (0.45, 10.1) | 0.34 |
|
| ||||||||||
| HPV 58 E6 | 4 | 9 | 8.71 (2.52, 30.2) | <0.001 | 76 | 56.3 (20.4, 155.8) | <0.001 | 2 | 2.71 (0.41, 18.1) | 0.30 |
| HPV 58 E7 | 17 | 13 | 1.43 (0.64, 3.21) | 0.38 | 11 | 2.24 (0.96, 5.23) | 0.06 | 6 | 1.53 (0.54, 4.35) | 0.42 |
Adjusted for age, race, gender, education, tobacco smoking, alcohol drinking, study phase and HPV16 (for all non-HPV16 types). HPV 52 and 58 E7 not adjusted for phase because they were only measured for phase 1.
Since the primary association with non-16 HPV types was of interest, we sought to remove any potential residual confounding by HPV16 infection by conducting a secondary analysis excluding all subjects with HPV16 seropositivity for L1, E6 and E7 (n=598). In this secondary analysis with 1578 subjects, an 8-fold increase in HNSCC risk was observed for HPV33 E6, a 4-fold increase in HNSCC risk for HPV18 E6, and a 3-fold increase in HNSCC risk for HPV52 E7 (Table 6). While most of the increase in HNSCC risk associated with non-HPV16 types was driven by pharyngeal cancer (e.g., HPV33 E6: OR = 18.9, 95% CI = 3.22–110.8; table 7), a statistically significant association was also observed for HPV52 and oral cavity cancer (E7 seropositive, OR = 4.79, 95% CI = 1.47–15.6) (Table 7).
Table 6.
Odds ratios and 95% CI for HPV 6, 11, 18, 31, 33, 45, 52, and 58 positive serology in relation to head and neck cancer among subjects who were seronegative for HPV16 (L1, E6, and E7).
| HPV type* | Case/Control Seropositive No. | OR (95% CI)** | p-value |
|---|---|---|---|
| HPV 6 L1 | 61/90 | 0.90 (0.62, 1.32) | 0.60 |
|
| |||
| HPV 11 L1 | 37/53 | 0.91 (0.56, 1.47) | 0.70 |
| HPV 11 E6 | 4/8 | 0.81 (0.20, 3.18) | 0.76 |
| HPV 11 E7 | 2/0 | NA | NA |
|
| |||
| HPV 18 L1 | 86/122 | 1.17 (0.85, 1.61) | 0.35 |
| HPV 18 E6 | 12/4 | 4.19 (1.26, 14.0) | 0.02 |
| HPV 18 E7 | 13/15 | 1.25 (0.56, 2.77) | 0.59 |
|
| |||
| HPV 31 L1 | 41/63 | 1.20 (0.78, 1.85) | 0.42 |
| HPV 31 E6 | 20/32 | 1.10 (0.59, 2.05) | 0.77 |
|
| |||
| HPV 33 L1 | 29/49 | 0.98 (0.60, 1.62) | 0.95 |
| HPV 33 E6 | 8/2 | 7.96 (1.56, 40.5) | 0.01 |
|
| |||
| HPV 45 L1 | 31/45 | 1.25 (0.76, 2.07) | 0.39 |
| HPV 45 E6 | 4/8 | 0.79 (0.21, 3.01) | 0.74 |
|
| |||
| HPV 52 E6 | 2/0 | NA | NA |
| HPV 52 E7 | 15/6 | 3.40 (1.16, 9.99) | 0.03 |
|
| |||
| HPV 58 E6 | 5/3 | 2.44 (0.51, 11.7) | 0.26 |
| HPV 58 E7 | 20/13 | 1.47 (0.64, 3.37) | 0.36 |
High-risk HPV include HPV18, 31, 33, 45, 52, and/or 58.
Adjusted for age, race, gender, education, smoking, alcohol drinking, and study phase.
Table 7.
Odds ratios and 95% CI for HPV 6, 11, 18, 31, 33, 45, 52, and 58 positive serology (E6, E7) in relation to different sites of head and neck cancer, among subjects who were seronegative for HPV16 (L1, E6, and E7).
| HPV type* | Controls, Sero- positive No. |
Oral cavity (N=311) Seropositive No. |
Oral cavity OR (95% CI) |
Oral cavity p-value |
Pharyngeal (N=164) Seropositive No. |
Pharyngeal OR (95% CI) |
Pharyngeal p-value |
Laryngeal (N=127) Seropositive No. |
Laryngeal OR (95% CI) |
Laryngeal p-value |
|---|---|---|---|---|---|---|---|---|---|---|
| HPV 11 E6 | 8 | 0 | NA | NA | 3 | 2.32 (0.49, 11.0) | 0.29 | 1 | 1.34 (0.16, 11.3) | 0.79 |
|
| ||||||||||
| HPV 18 E6 | 4 | 6 | 2.96 (0.72, 12.1) | 0.13 | 5 | 8.25 (2.10, 32.4) | 0.002 | 1 | 2.14 (0.23, 19.9) | 0.50 |
| HPV 18 E7 | 15 | 6 | 1.14 (0.42, 3.12) | 0.79 | 4 | 1.69 (0.53, 5.42) | 0.38 | 3 | 1.19 (0.32, 4.46) | 0.79 |
|
| ||||||||||
| HPV 31 E6 | 32 | 12 | 1.37 (0.67, 2.81) | 0.39 | 2 | 0.32 (0.07, 1.55) | 0.16 | 6 | 1.35 (0.51, 3.55) | 0.55 |
|
| ||||||||||
| HPV 33 E6 | 2 | 2 | 4.99 (0.64, 38.9) | 0.13 | 4 | 18.9 (3.22, 110.8) | 0.001 | 2 | 7.62 (0.84, 69.3) | 0.07 |
|
| ||||||||||
| HPV 45 E6 | 8 | 0 | NA | NA | 3 | 2.77 (0.66, 11.7) | 0.17 | 1 | 0.60 (0.06, 5.90) | 0.66 |
|
| ||||||||||
| HPV 52 E7 | 6 | 8 | 4.79 (1.47, 15.6) | 0.01 | 4 | 3.02 (0.71, 12.9) | 0.14 | 3 | 2.82 (0.57, 13.9) | 0.20 |
|
| ||||||||||
| HPV 58 E6 | 3 | 1 | 0.81 (0.08, 8.60) | 0.86 | 4 | 7.30 (1.42, 37.7) | 0.02 | 0 | NA | NA |
| HPV 58 E7 | 13 | 11 | 1.65 (0.65, 4.21) | 0.29 | 5 | 1.62 (0.47, 5.59) | 0.45 | 4 | 1.31 (0.36, 4.69) | 0.68 |
High-risk HPV include HPV18, 31, 33, 45, 52, and/or 58. HPV52 E6 had no seropositive controls.
Adjusted for age, race, gender, education, smoking, alcohol drinking and study phase.
We investigated whether there was any evidence of an interaction between HPV16 seropositivity and high-risk non-HPV16 types. A multiplicative interaction was observed between HPV16 E6 and high-risk HPV (p=0.007); subjects with a positive serology for HPV16 and non-HPV16 high-risk HPV E6 types had a 85-fold increase in risk of HNSCC compared to those with no high-risk HPV infection (OR = 84.6, 95% CI = 20.3–352.4), while positive serology for HPV16 E6 or other high-risk HPV E6 alone conferred lower increases in risk (HPV16 E6 only, OR = 20.5, 95% CI = 12.8–33.0; high-risk non-HPV16 E6 only, OR = 1.80, 95% CI = 1.17–2.76). Similarly, we observed a dose-response increase in risk with additional high-risk HPV infections (OR = 5.04, 95% CI = 3.85–6.59, for seropositive with 1 high risk HPV; OR = 19.3, 95% CI = 10.5–36.0, for seropositive with 2 high risk HPVs; OR = 169, 95% 23–1226, for seropositive with 3 or more HPVs compared to no seropositive HPV infections).
Since we 19, 20 and others 21–23 have shown that a history of allergy and a history of periodontal disease are independently associated with head and neck cancer risk (and since a humoral response could play a role in disease among those infected with HPV), we examined the data for evidence of a potential interaction between these two medical conditions and high-risk HPV infection (including HPV16). However, we found no evidence of any significant interaction between history of allergy or history of periodontal disease with HPV infection (data not shown).
Discussion
In this large US case-control study, we observed positive associations for several high-risk, non-HPV 16 types (i.e., HPV18 E6, HPV33 E6, HPV52 E7) and risk of HNSCC among seronegative HPV16 individuals. Statistically significant associations were observed for HPV18 E6, HPV33 E6 and HPV58 E7 and pharyngeal cancer, but not for other tumor sites. However, a statistically significant association was observed for HPV52 E7 and risk of oral cavity cancer. Finally, we observed a strong interaction between HPV16 E6 and other high-risk non-HPV16 types (E6), and increasing magnitude of risk for HNSCC with additional number of high-risk HPV seropositive infections.
The largest study, to date, to examine serology for non-HPV16 types (HPV6, 11, 18, 31, 33, 35, 45, 52, 58) and risk of HNSCC, reported statistically significant positive associations for HPV31, 33, 35, 52, and 58; moreover, after excluding subjects seropositive for HPV16 E6/E7, a strong association remained for HPV52 and oropharyngeal cancer (OR = 9.15, 95% CI = 1.87–44.8) 12. Statistically significant associations for non-HPV16 types, among HPV16 seronegative subjects, were also observed in a large pooled case-control study (ARCAGE) for HPV18 E6 and HPV52 E7 and risk of oropharyngeal cancer 13. Serology for HPV58 was not measured in the ARCAGE study, and no increase in risk was observed with HPV33 E7; however a statistically non-significant positive association was observed for HPV33 L1 and oropharyngeal cancer (OR = 1.97, 95% CI = 0.78–4.97) 13. In a European prospective cohort study, a statistically significant association between HPV33 E6 positive serology and risk of larynx cancer was observed among HPV16 seronegative subjects 24, which is consistent with the 7-fold increased risk for laryngeal cancer in this study, although our finding was not statistically significant (p=0.07; Table 5). However, small numbers of oropharnygeal cases limited power to analyze non-HPV16 associations among seronegative HPV16 subjects in that cohort study 24.
Three additional studies reported positive associations for HNSCC risk (overall or for oropharyngeal) and serology of non-HPV 16 types (L1/L2 antibodies), including HPV18, 31 25, 33 26, and 35 9, although another study reported no associations for HPV18, 33, and 73 27. In a previous report based on Phase I of this case-control study, we found positive associations for both HPV6 (a ‘low-risk’ virus) and HPV18 and risk of HNSCC after adjusting for HPV16 seropositivity 6. In our current analysis, which includes an additional 521 incident HNSCC cases (and 559 controls), we observed a 54% increase risk for HPV6 L1 after controlling for HPV16, but the association was no longer present after controlling for other HPV types (Table 3).
Associations between HPV16 and oropharyngeal cancer have been consistently observed, and HPV16 has been confirmed by IARC as Group 1 carcinogen (evidence is convincing) for oropharyngeal and oral cancer 28. In contrast, HPV16 has been less consistently linked to laryngeal cancer and the 2012 IARC monographs concludes that “evidence is not conclusive” for this cancer 28. In this study, we observed statistically significant association for HPV16 and laryngeal cancer, suggesting that HPV infection is indeed etiologically important in this tumor type; strong associations with HPV16 and laryngeal cancer were also recently reported in the ARCAGE study 13.
Viral proteins produced by HPVs are known to interact with key tumor suppressor proteins, such as p53 and RB, resulting in dysregulation of cell cycle control and delayed epithelial cell differentiation 11. In addition, expression of viral oncoproteins E6 and E7 can lead to genomic instability, which may contribute to HPV persistence and accumulation of oncogene mutations 29. HPVs also have a unique ability to evade the immune response, using a battery of different mechanisms, including blocking interferon activity, establishing cytotoxic T lymphocyte (CTL) tolerance, reducing CD8+-mediated response by downregulating IL18 expression, and disrupting antigen processing and presentation in antigen-presenting cells (APCs) 30. Mechanisms by which different HPV early proteins interact with host proteins and impact the immune response and other cellular processes are still being unraveled. New data suggest that similar viral proteins (e.g., E7) may behave differently within the same HPV genus 31. Consequently, the presence of more than one type of high-risk HPV could provide opportunity for tumorigenesis through interaction of multiple viral proteins having different impacts on the host; this may explain the 85-fold increase in HNSCC risk that we observed for combined infection with high-risk HPVs and HPV16 and for the increase in magnitude of risk with additional number of infections.
The strengths of this study include the second largest study to date measuring multiple high-risk HPV types and risk of head and neck cancer. Furthermore, detailed data on potential confounders, including smoking, alcohol consumption and HPV16 status, allowed for examination of independent associations and potential interactions by these risk factors. Seroprevalence of HPV16 infection based on serology in this population was as expected and similar to previous studies 9, 26. Serology-based measures of HPV16 (E6/E7) have been shown to have high specificity for oncogenic HPV infections and provide similar or better estimates of clinical outcome in the oropharynx when compared with DNA based measures 32, 33. Moreover, given that DNA-based measures are unreliable in the larynx, with a reproducibility of 32% 34, serology provides a more sensitive test that is necessary to allow for the detection of lower relative risks.
This study had some limitations, including a retrospective study design with a lower response rate in the controls than in the cases, a largely Caucasian population, and potential confounding by other types of HPV that were not measured. While we cannot exclude the possibility that the results were influenced by the lower response rates among controls, we observed associations for HPV16 that are consistent with the existing literature, suggesting the response rate did not substantially alter the associations. Another limitation to our study was the small number of cases/controls that were infected with some of the subtypes of HPV; while some of findings were statistically significant for rarer subtypes of HPV, large risk estimates should be interpreted with caution and larger or pooled studies should provide more stable risk estimates for those associations. In this study, we chose HPV types that have been associated with cancer; we were not able to measure all HPV subtypes and regions due to budgetary constraints. Consequently, we cannot rule out the possibility that unmeasured HPV types were confounding the associations reported. More studies will be necessary to examine these associations in non-Caucasian populations.
In this large population-based case-control study, we confirm strong associations between HPV16 E6 seropositivity and risk of oral cavity, pharyngeal and laryngeal cancers. In addition, HPV types 18, 33, and 52, were strongly associated with HNSCC, and particularly pharyngeal cancer, and associations remained statistically significant after excluding HPV16 seropositive subjects, supporting the role for non-HPV16 subtypes in the etiology of HNSCC.
Novelty.
Our findings suggest that HPV18, 33 and 52 seropositivity is strongly associated with HNSCC independently of HPV16, and that HPV16 seropositivity is associated with oral cavity and laryngeal cancers, as well as pharyngeal cancers
Impact: Understanding role of HPV in HNSCC is crucial to developing prevention strategies and providing targeted treatment.
Acknowledgments
Funding: NIH [CA078609, CA100679] and Flight Attendants Medical Research Institute
References
- 1.Howlader N, Noone AM, Krapcho M, Garshell J, Neyman N, Altekruse SF, Kosary CL, Yu M, Ruhl J, Tatalovich Z, Cho H, Mariotto A, et al. SEER Cancer Statistics Review, 1975–2010. Bethesda, MD: National Cancer Institute; 2013. vol. http://seer.cancer.gov/csr/1975_2010. [Google Scholar]
- 2.de Souza DL, de Camargo Cancela M, Perez MM, Curado MP. Trends in the incidence of oral cavity and oropharyngeal cancers in Spain. Head & neck. 2012;34:649–54. doi: 10.1002/hed.21793. [DOI] [PubMed] [Google Scholar]
- 3.Blomberg M, Nielsen A, Munk C, Kjaer SK. Trends in head and neck cancer incidence in Denmark, 1978–2007: focus on human papillomavirus associated sites. Int J Cancer. 2011;129:733–41. doi: 10.1002/ijc.25699. [DOI] [PubMed] [Google Scholar]
- 4.Chaturvedi AK, Engels EA, Anderson WF, Gillison ML. Incidence trends for human papillomavirus-related and -unrelated oral squamous cell carcinomas in the United States. J Clin Oncol. 2008;26:612–9. doi: 10.1200/JCO.2007.14.1713. [DOI] [PubMed] [Google Scholar]
- 5.Carvalho AL, Nishimoto IN, Califano JA, Kowalski LP. Trends in incidence and prognosis for head and neck cancer in the United States: a site-specific analysis of the SEER database. Int J Cancer. 2005;114:806–16. doi: 10.1002/ijc.20740. [DOI] [PubMed] [Google Scholar]
- 6.Furniss CS, McClean MD, Smith JF, Bryan J, Applebaum KM, Nelson HH, Posner MR, Kelsey KT. Human papillomavirus 6 seropositivity is associated with risk of head and neck squamous cell carcinoma, independent of tobacco and alcohol use. Ann Oncol. 2009;20:534–41. doi: 10.1093/annonc/mdn643. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 7.Smith EM, Hoffman HT, Summersgill KS, Kirchner HL, Turek LP, Haugen TH. Human papillomavirus and risk of oral cancer. The Laryngoscope. 1998;108:1098–103. doi: 10.1097/00005537-199807000-00027. [DOI] [PubMed] [Google Scholar]
- 8.Gillison ML, Koch WM, Capone RB, Spafford M, Westra WH, Wu L, Zahurak ML, Daniel RW, Viglione M, Symer DE, Shah KV, Sidransky D. Evidence for a causal association between human papillomavirus and a subset of head and neck cancers. J Natl Cancer Inst. 2000;92:709–20. doi: 10.1093/jnci/92.9.709. [DOI] [PubMed] [Google Scholar]
- 9.Gillison ML, D’Souza G, Westra W, Sugar E, Xiao W, Begum S, Viscidi R. Distinct risk factor profiles for human papillomavirus type 16-positive and human papillomavirus type 16-negative head and neck cancers. J Natl Cancer Inst. 2008;100:407–20. doi: 10.1093/jnci/djn025. [DOI] [PubMed] [Google Scholar]
- 10.Applebaum KM, Furniss CS, Zeka A, Posner MR, Smith JF, Bryan J, Eisen EA, Peters ES, McClean MD, Kelsey KT. Lack of association of alcohol and tobacco with HPV16-associated head and neck cancer. J Natl Cancer Inst. 2007;99:1801–10. doi: 10.1093/jnci/djm233. [DOI] [PubMed] [Google Scholar]
- 11.Munoz N, Castellsague X, de Gonzalez AB, Gissmann L. Chapter 1: HPV in the etiology of human cancer. Vaccine. 2006;24 (Suppl 3):S3/1–10. doi: 10.1016/j.vaccine.2006.05.115. [DOI] [PubMed] [Google Scholar]
- 12.Ribeiro KB, Levi JE, Pawlita M, Koifman S, Matos E, Eluf-Neto J, Wunsch-Filho V, Curado MP, Shangina O, Zaridze D, Szeszenia-Dabrowska N, Lissowska J, et al. Low human papillomavirus prevalence in head and neck cancer: results from two large case-control studies in high-incidence regions. Int J Epidemiol. 2011;40:489–502. doi: 10.1093/ije/dyq249. [DOI] [PubMed] [Google Scholar]
- 13.Anantharaman D, Gheit T, Waterboer T, Abedi-Ardekani B, Carreira C, McKay-Chopin S, Gaborieau V, Marron M, Lagiou P, Ahrens W, Holcatova I, Merletti F, et al. Human papillomavirus infections and upper aero-digestive tract cancers: the ARCAGE study. J Natl Cancer Inst. 2013;105:536–45. doi: 10.1093/jnci/djt053. [DOI] [PubMed] [Google Scholar]
- 14.Meschede W, Zumbach K, Braspenning J, Scheffner M, Benitez-Bribiesca L, Luande J, Gissmann L, Pawlita M. Antibodies against early proteins of human papillomaviruses as diagnostic markers for invasive cervical cancer. Journal of clinical microbiology. 1998;36:475–80. doi: 10.1128/jcm.36.2.475-480.1998. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 15.Sehr P, Muller M, Hopfl R, Widschwendter A, Pawlita M. HPV antibody detection by ELISA with capsid protein L1 fused to glutathione S-transferase. J Virol Methods. 2002;106:61–70. doi: 10.1016/s0166-0934(02)00134-9. [DOI] [PubMed] [Google Scholar]
- 16.Rubin DB, Schenker N. Multiple imputation in health-care databases: an overview and some applications. Stat Med. 1991;10:585–98. doi: 10.1002/sim.4780100410. [DOI] [PubMed] [Google Scholar]
- 17.Greenland S, Finkle WD. A critical look at methods for handling missing covariates in epidemiologic regression analyses. Am J Epidemiol. 1995;142:1255–64. doi: 10.1093/oxfordjournals.aje.a117592. [DOI] [PubMed] [Google Scholar]
- 18.Su Y-S, Gelman A, Hill J, Yajima M. Multiple Imputation with Diagnostics (mi) in R: Opening Windows into the Black Box. Journal of Statistical Software. 2011;45:1–31. [Google Scholar]
- 19.Michaud DS, Langevin SM, Eliot M, Nelson HH, McClean MD, Christensen BC, Marsit CJ, Kelsey KT. Allergies and risk of head and neck cancer. Cancer Causes Control. 2012;23:1317–22. doi: 10.1007/s10552-012-0009-8. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 20.Eliot MN, Michaud DS, Langevin SM, McClean MD, Kelsey KT. Periodontal disease and mouthwash use are risk factors for head and neck squamous cell carcinoma. Cancer Causes Control. 2013 doi: 10.1007/s10552-013-0209-x. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 21.Vena JE, Bona JR, Byers TE, Middleton E, Jr, Swanson MK, Graham S. Allergy-related diseases and cancer: an inverse association. Am J Epidemiol. 1985;122:66–74. doi: 10.1093/oxfordjournals.aje.a114087. [DOI] [PubMed] [Google Scholar]
- 22.Bosetti C, Talamini R, Franceschi S, Negri E, Giacosa A, La Vecchia C. Allergy and the risk of selected digestive and laryngeal neoplasms. Eur J Cancer Prev. 2004;13:173–6. doi: 10.1097/01.cej.0000130016.85687.cf. [DOI] [PubMed] [Google Scholar]
- 23.Tezal M, Sullivan MA, Hyland A, Marshall JR, Stoler D, Reid ME, Loree TR, Rigual NR, Merzianu M, Hauck L, Lillis C, Wactawski-Wende J, et al. Chronic periodontitis and the incidence of head and neck squamous cell carcinoma. Cancer Epidemiol Biomarkers Prev. 2009;18:2406–12. doi: 10.1158/1055-9965.EPI-09-0334. [DOI] [PubMed] [Google Scholar]
- 24.Kreimer AR, Johansson M, Waterboer T, Kaaks R, Chang-Claude J, Drogen D, Tjonneland A, Overvad K, Quiros JR, Gonzalez CA, Sanchez MJ, Larranaga N, et al. Evaluation of human papillomavirus antibodies and risk of subsequent head and neck cancer. J Clin Oncol. 2013;31:2708–15. doi: 10.1200/JCO.2012.47.2738. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 25.Pintos J, Black MJ, Sadeghi N, Ghadirian P, Zeitouni AG, Viscidi RP, Herrero R, Coutlee F, Franco EL. Human papillomavirus infection and oral cancer: a case-control study in Montreal, Canada. Oral oncology. 2008;44:242–50. doi: 10.1016/j.oraloncology.2007.02.005. [DOI] [PubMed] [Google Scholar]
- 26.Smith EM, Ritchie JM, Pawlita M, Rubenstein LM, Haugen TH, Turek LP, Hamsikova E. Human papillomavirus seropositivity and risks of head and neck cancer. Int J Cancer. 2007;120:825–32. doi: 10.1002/ijc.22330. [DOI] [PubMed] [Google Scholar]
- 27.Mork J, Lie AK, Glattre E, Hallmans G, Jellum E, Koskela P, Moller B, Pukkala E, Schiller JT, Youngman L, Lehtinen M, Dillner J. Human papillomavirus infection as a risk factor for squamous-cell carcinoma of the head and neck. N Engl J Med. 2001;344:1125–31. doi: 10.1056/NEJM200104123441503. [DOI] [PubMed] [Google Scholar]
- 28.A Review of Human Carcinogens. B. Biological Agentsed. 100B. IARC (WHO); 2012. [Google Scholar]
- 29.Duensing S, Munger K. Mechanisms of genomic instability in human cancer: insights from studies with human papillomavirus oncoproteins. Int J Cancer. 2004;109:157–62. doi: 10.1002/ijc.11691. [DOI] [PubMed] [Google Scholar]
- 30.Tindle RW. Immune evasion in human papillomavirus-associated cervical cancer. Nat Rev Cancer. 2002;2:59–65. doi: 10.1038/nrc700. [DOI] [PubMed] [Google Scholar]
- 31.White EA, Sowa ME, Tan MJ, Jeudy S, Hayes SD, Santha S, Munger K, Harper JW, Howley PM. Systematic identification of interactions between host cell proteins and E7 oncoproteins from diverse human papillomaviruses. Proc Natl Acad Sci U S A. 2012;109:E260–7. doi: 10.1073/pnas.1116776109. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 32.Liang C, Marsit CJ, McClean MD, Nelson HH, Christensen BC, Haddad RI, Clark JR, Wein RO, Grillone GA, Houseman EA, Halec G, Waterboer T, et al. Biomarkers of HPV in head and neck squamous cell carcinoma. Cancer Res. 2012;72:5004–13. doi: 10.1158/0008-5472.CAN-11-3277. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 33.Holzinger D, Flechtenmacher C, Henfling N, Kaden I, Grabe N, Lahrmann B, Schmitt M, Hess J, Pawlita M, Bosch FX. Identification of oropharyngeal squamous cell carcinomas with active HPV16 involvement by immunohistochemical analysis of the retinoblastoma protein pathway. Int J Cancer. 2013;133:1389–99. doi: 10.1002/ijc.28142. [DOI] [PubMed] [Google Scholar]
- 34.Halec G, Holzinger D, Schmitt M, Flechtenmacher C, Dyckhoff G, Lloveras B, Hofler D, Bosch FX, Pawlita M. Biological evidence for a causal role of HPV16 in a small fraction of laryngeal squamous cell carcinoma. Br J Cancer. 2013;109:172–83. doi: 10.1038/bjc.2013.296. [DOI] [PMC free article] [PubMed] [Google Scholar]